Paulinelli Régis Resende, Freitas-Junior Ruffo, Rahal Rosemar Macedo de Souza, Oliveira Luis Fernando de Pádua, Vilela Maria Helena Tavares, Moreira Marise Amaral Rebouças, Alves Katyane Larissa, Peleja Marina Berquó, Resende Tatiane Coelho Capel de
MD, PhD, Mastology Program, Department of Gynecology and Obstetrics, Universidade Federal de Goiás (UFG), Goiânia, GO, Brazil.
MD, MsM, Mastology Program, Department of Gynecology and Obstetrics, UFG, Goiânia, GO, Brazil.
Rev Assoc Med Bras (1992). 2017 Feb;63(2):118-123. doi: 10.1590/1806-9282.63.02.118.
: Methylene blue is more widely available and less expensive than patent blue, with an apparently lower risk of anaphylaxis.
: The two dyes were compared regarding detection of the sentinel lymph node (SLN).
: A prospective, randomized trial involved 142 patients with invasive breast carcinoma. Sixty-nine (49.3%) assigned to patent blue (group A) and 71 (50.70%) to methylene blue (group B). Thirty-five patients (25.0%) were clinical stage III or IV; 55 (38.7%) had axillary lymph nodes affected; and 69 (49.3%) underwent neoadjuvant chemotherapy. Two patients were excluded because the dye type was not recorded.
: Patients and tumor characteristics were similar in both groups. SLNs were identified in 47 women (68.1%) in group A and 43 (60.6%) in group B (p=0.35). SLNs were affected in 22 cases (51.2%) in group A and 21 (48.8%) in group B (p=0.62). The SLN was the only node affected in 12 cases (54.5%) in group A and six (33.3%) in group B (p=0.18). The time and degree of difficulty involved in identifying the SLN were similar in both groups. There were no complications or allergies.
: Methylene blue performed as well as patent blue in identifying the SLN in breast cancer patients.
亚甲蓝比专利蓝更容易获得且成本更低，过敏反应风险明显更低。
比较这两种染料在前哨淋巴结（SLN）检测方面的情况。
一项前瞻性随机试验纳入了142例浸润性乳腺癌患者。69例（49.3%）分配至专利蓝组（A组），71例（50.7%）分配至亚甲蓝组（B组）。35例患者（25.0%）为临床III期或IV期；55例（38.7%）腋窝淋巴结受累；69例（49.3%）接受了新辅助化疗。2例患者因未记录染料类型而被排除。
两组患者和肿瘤特征相似。A组47例女性（68.1%）检测到前哨淋巴结，B组43例（60.6%）（p = 0.35）。A组22例（51.2%）前哨淋巴结受累，B组21例（48.8%）（p = 0.62）。A组12例（54.5%）前哨淋巴结是唯一受累淋巴结，B组6例（33.3%）（p = 0.18）。两组在前哨淋巴结识别时间和难度程度方面相似。未出现并发症或过敏反应。
在乳腺癌患者前哨淋巴结识别方面，亚甲蓝与专利蓝表现相当。
